Empirical Asset Management’s Harvard Bioscience HBIO Stock Holding History

Empirical Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,000	Closed	-$84K	–	174
2023 Q1	$84K	Hold	2,000	–	–	0.08%	142
2022 Q4	$55.4K	Hold	2,000	–	–	0.06%	152
2022 Q3	$51K	Buy	2,000 +1,000	+100%	+$33.1K	0.06%	144
2022 Q2	$36K	Buy	+1,000	New	+$45.1K	0.04%	152

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Empirical Asset Management's HBIO Position: Q2 2023 in Review

Empirical Asset Management sold out of Harvard Bioscience (HBIO) in Q2 2023, closing a stake of 2,000 shares — an estimated $84K sold.

Empirical Asset Management first reported a position in HBIO in Q2 2022 and held it in 4 quarters. The position peaked at $84K in Q1 2023. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2023.

Empirical Asset Management reported no remaining Harvard Bioscience position as of Q2 2023 after selling out during the quarter.
Empirical Asset Management sold 2,000 Harvard Bioscience shares in Q2 2023, an estimated $84K.
Empirical Asset Management first reported a position in Harvard Bioscience in Q2 2022 and held it in 4 quarters.
Empirical Asset Management's Harvard Bioscience position peaked at $84K in Q1 2023.
100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2023.

Based on Empirical Asset Management's 13F filing for Q2 2023, filed 1 Aug 2023.